Early prediction of gross hemorrhagic transformation by noncontrast agent MRI cluster analysis after embolic stroke in rat

Stroke. 2005 Jun;36(6):1247-52. doi: 10.1161/01.STR.0000166199.10017.c5. Epub 2005 May 5.

Abstract

Background and purpose: Our goal was to develop magnetic resonance indices, without image contrast agent enhancement, that predict hemorrhagic transformation (HT) in a rat model of embolic stroke.

Methods: Male Wistar rats subjected to embolic stroke with (n=12) or without (n=10) the combination treatment with recombinant tissue plasminogen activator and an anti-platelet glycoprotein IIb/IIIa antibody 7E3 F(ab')2 initiated at 4 hours after onset of stroke were investigated using a 7-T MRI system. Radiofrequency saturation T1 (T1sat) maps with magnetization transfer, apparent diffusion coefficient of water (ADCw) maps in 3 directions, and T2 maps were measured at 2, 24, and 48 hours after embolization. MRI data were analyzed individually and using 2D cluster plots. Histological measurements were obtained at 48 hours.

Results: Gross hemorrhage was detected at 48 hours in 7 (4 control, 3 treated) of 22 animals. The 2D cluster plot using MRI T1sat and ADCw maps obtained at 2 hours after stroke predicted all gross HT. The location of gross hemorrhage predicted by the 2D cluster plot was within 0.75 mm of the identifying MRI cluster.

Conclusions: The 2D MRI cluster plot analysis using T1sat and ADCw maps acquired at 2 hours after the onset of embolic stroke predicts gross HT.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Blood-Brain Barrier
  • Cluster Analysis
  • Combined Modality Therapy
  • Disease Models, Animal*
  • Hemorrhage / diagnosis*
  • Hemorrhage / pathology*
  • Immunotherapy
  • Magnetic Resonance Imaging / methods*
  • Male
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex / immunology
  • Predictive Value of Tests
  • Rats
  • Rats, Wistar
  • Recombinant Proteins / therapeutic use
  • Stroke / diagnosis*
  • Stroke / pathology*
  • Time Factors
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Recombinant Proteins
  • Tissue Plasminogen Activator